<DOC>
	<DOCNO>NCT02448524</DOCNO>
	<brief_summary>- To evaluate safety efficacy MiStent drug ( sirolimus ) -eluting stent system treatment coronary heart disease ( CHD ) patient primary situ CHD ( de novo ) ; - To evaluate operating performance MiStent drug ( sirolimus ) -eluting coronary stent system .</brief_summary>
	<brief_title>Clinical Trial Efficacy Safety Sirolimus-Eluting Stent ( MiStent® System )</brief_title>
	<detailed_description>- The study enroll total 428 case primary situ coronary artery disease patient ( patient enrol maximum two target lesion different blood vessel maximum 2 stent per lesion . If stent need implantation , stent brand require , mix brand allow patient except salvage implantation brand stent . ) - Lesions reference diameter 2.5mm-3.5mm ( visual measurement ) length ≤40mm ( visual measurement ) select , subject meet inclusion exclusion criterion agree participate enrol . - Prospective , single-blinded , multi-center , randomize , control clinical trial ; - Patients situ primary CHD ; - Clinical site : 18 ; patient enrol 1:1 ratio ( i.e. , 214 case enrol group , MiStent stent group TIVOLI stent group ) ; - Clinical follow-up time point : 1 month , 6 month , 9 month , 12 month yearly 2-5 year post index procedure ; - Angiographic follow-up 9 month post index procedure ; in-stent late lumen loss measure quantitative coronary angiography ( QCA ) use primary efficacy endpoint product evaluation ; - In trial , collection , collation , statistical analysis adjudication relevant clinical angiographic data conduct independent coronary angiography core laboratory ( CCRF Medical Technology Co. , Ltd. ) , data management statistical center , clinical event committee clinical audit agency . All patient follow 5 year ( telephone outpatient form ) , incidence adverse event record allow accurate reliable evaluation long-term safety MiStentTM drug ( sirolimus ) elute coronary stent system .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Stable unstable angina pectoris ( AP ) , old myocardial infarction ( OMI ) , confirm evidence myocardial ischemia ; Primary situ coronary artery lesion ( two target lesion 2 stent per lesion ) ; Visual target lesion length ≤40mm ; Visual reference vessel diameter 2.53.5mm ; Visual diameter stenosis ≥70 % ; Patients indication coronary artery bypass surgery ( CABG ) ; Subjects participate voluntarily sign informed consent willing accept angiographic clinical followup . Acute myocardial infarction ( AMI ) occur within 7 day prior procedure ; postMI complicate elevated level cardiac enzyme ( CKMB , cTNT / I ) ; CTO ( TIMI0 ) lesion , leave main lesion , ostial lesion , bypass graft lesion , bifurcation lesion ( lateral side branch reference vessel diameter≥2.5mm ) , restenosis instent threevessel disease need treat ; Severe calcify lesion balloon predilation expect unsuccessful ; Tortuous lesion render stent cross difficult ; NYHA class≥III leave ventricular ejection fraction &lt; 40 % ; Implantation stent past year ; Pregnant breastfeeding patient patient plan get pregnant within follow year ; Subjects bleeding tendency coagulation disorder PCI contraindication / anticoagulant therapy contraindication tolerate dual antiplatelet treatment within year date ; Presence disease ( cancer , malignancy , congestive heart failure , organ transplantation candidate ) history substance abuse ( alcohol , cocaine , heroin , etc . ) , poor protocol compliance life expectancy le 1 year ; Allergic one following : aspirin , heparin , clopidogrel , sirolimus ( rapamycin ) , PLGA polymer , contrast agent metal ; Severe liver kidney dysfunction ( ALT AST level 3 time great upper limit normal ; eGFR &lt; 30ml/min ) ; Patients participate clinical trial complete followup primary endpoint ; Study subject poor compliance judge investigator , poor possibility complete study accordance requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Treatment</keyword>
	<keyword>patient</keyword>
	<keyword>primary situ CHD ( de novo ) lesion</keyword>
</DOC>